Your session is about to expire
← Back to Search
T-VEC for Pancreatic Cancer
Study Summary
This trial is looking at whether or not a certain medication is safe to give to people with pancreatic cancer, and if it is effective in shrinking tumors or preventing their growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 437 Patients • NCT00769704Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery recently.My condition did not improve with the first round of chemotherapy using 5-fluorouracil or gemcitabine.I am a male and will either not have sex or use a condom with women who can get pregnant.My pancreatic cancer is not expected to stop me from completing the study.I have not had any other cancer besides skin cancer in the last 3 years.I have no lasting side effects from previous cancer treatments.I am receiving treatment for an active autoimmune disease.I have active herpes skin sores or complications.I have been treated with specific therapies before.I have been diagnosed with specific infections or illnesses.I have had pancreatitis recently or it's still active.I am 18 years old or older.I can take care of myself and am up and about more than half of my waking hours.My pancreatic cancer can be measured and is at least 1cm big.My organs and bone marrow are working well.I am considered fit for multiple endoscopy procedures by a specialist.You have a weakened immune system that can cause serious health problems.I haven't had any severe infections recently.My pancreatic cancer is advanced and cannot be removed by surgery.You are not willing to reduce contact with people who are at a greater risk for complications caused by HSV-1.I am committed to not having heterosexual intercourse or will use effective birth control.I have not had chemotherapy or radiotherapy recently.I have not had radiation to my abdomen recently.My pancreatic cancer is cystic, possibly with many small cysts.I have not received a live vaccine recently.I am currently taking Coumadin.
- Group 1: T-Vec
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please provide an overview of prior investigations regarding Talimogene laherparepvec?
"Presently, 22 research trials are assessing Talimogene laherparepvec with none currently in phase 3. Although most of these studies take place at a Santa Monica, California location, 242 clinical trial sites have studied this drug."
Is this experimental research the inaugural effort of its kind?
"Currently, 22 clinical trials for Talimogene laherparepvec are operational in 93 cities and 16 countries. The earliest trial of its kind took place in 2015 under Amgen's sponsorship; this involved a cohort of 30 participants across two phases to receive drug approval. Since then, 13 studies have been finalized."
Does Talimogene laherparepvec present any imminent risks to individuals?
"Due to the fact that Talimogene laherparepvec is currently in the first stage of clinical trials, there isn't a large amount of evidence supporting its safety and efficacy. As such, it received score of 1 on our scale from 1-3."
Are there any openings for volunteers in this experiment?
"As per the details on clinicaltrials.gov, this medical study is not actively recruiting patients at present. The trial was first posted in November 2017 and last updated in late 2022. However, there are numerous other research projects currently enrolling participants across 722 sites."
What is the aggregate size of the cohort participating in this clinical trial?
"Unfortunately, this investigation is not currently enrolling participants. While the trial was first published on November 16th 2017 and last edited on November 29th 2022, there are a multitude of other trials for cancer of pancreas (700) and Talimogene laherparepvec (22)."
Share this study with friends
Copy Link
Messenger